AKBA

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Akebia Ther

NASDAQ | AKBA

2.28

USD

$0.00

(

0.00%

)

At Close (As of Oct 29, 2025)

$840.51M

Market Cap

-

P/E Ratio

-0.18

EPS

$4.07

52 Week High

$1.52

52 Week Low

HEALTHCARE

Sector

AKBA Chart

Recent Chart
Price Action

AKBA Technicals

Tags:

AKBA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $97M
Total Revenue $160M
Cost Of Revenue $63M
Costof Goods And Services Sold $63M
Operating Income -$50M
Selling General And Administrative $102M
Research And Development $38M
Operating Expenses $185M
Investment Income Net -
Net Interest Income -$18M
Interest Income -
Interest Expense $18M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $38M
Income Before Tax -$69M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$69M
Comprehensive Income Net Of Tax -
Ebit -$51M
Ebitda -$14M
Net Income -$69M

Revenue & Profitability

Earnings Performance

AKBA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $221M
Total Current Assets $114M
Cash And Cash Equivalents At Carrying Value $52M
Cash And Short Term Investments $52M
Inventory $16M
Current Net Receivables $34M
Total Non Current Assets $107M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill $59M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $11M
Other Non Current Assets -
Total Liabilities $270M
Total Current Liabilities $81M
Current Accounts Payable $15M
Deferred Revenue -
Current Debt -
Short Term Debt $5.4M
Total Non Current Liabilities $189M
Capital Lease Obligations $8.9M
Long Term Debt $39M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $48M
Other Current Liabilities $45M
Other Non Current Liabilities $104M
Total Shareholder Equity -$49M
Treasury Stock -
Retained Earnings -$1.7B
Common Stock $2K
Common Stock Shares Outstanding $211M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$41M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $38M
Capital Expenditures $33K
Change In Receivables -
Change In Inventory -$28M
Profit Loss -
Cashflow From Investment -$33K
Cashflow From Financing $50M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$1.3M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$69M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $97M
Total Revenue $160M
Cost Of Revenue $63M
Costof Goods And Services Sold $63M
Operating Income -$50M
Selling General And Administrative $102M
Research And Development $38M
Operating Expenses $185M
Investment Income Net -
Net Interest Income -$18M
Interest Income -
Interest Expense $18M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $38M
Income Before Tax -$69M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$69M
Comprehensive Income Net Of Tax -
Ebit -$51M
Ebitda -$14M
Net Income -$69M

AKBA News

AKBA Profile

Akebia Ther Profile

Sector: HEALTHCARE

Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC

Akebia Therapeutics, Inc. (AKBA), based in Cambridge, Massachusetts, is a biopharmaceutical leader focused on developing and commercializing innovative therapies for chronic kidney disease. The company has a strong pipeline that targets significant unmet medical needs in renal care, leveraging advanced research and strategic partnerships to deliver effective treatment solutions. With its commitment to improving patient outcomes, Akebia is well-positioned to make a substantial impact in the evolving healthcare industry.

PPBT
+57.04%
$0.91
CMBM
+259.22%
$2.22
GPUS
-24.33%
$0.41
NVDA
+3.31%
$207.70
ERNA
+54.53%
$1.93
SOFI
+5.53%
$31.66
BYND
-5.56%
$1.86
PFSA
+5.44%
$0.30
VHAI
-25.00%
$0.00
NOK
-5.27%
$7.36
MSAI
+28.82%
$1.09
ASST
-9.72%
$1.30
YDKG
-6.65%
$0.05
PLUG
+3.93%
$2.89
KDLY
-8.99%
$0.91
FI
-40.78%
$74.71
F
+1.22%
$13.29
AXDX
-61.36%
$0.03
BURU
-6.02%
$0.35
DNN
+3.90%
$3.19
VSEE
+12.26%
$1.19
INTC
+0.20%
$41.61
FUBO
+3.98%
$3.78
T
-2.15%
$25.14
YYGH
+13.41%
$0.33
ADAP
-15.14%
$0.05
WTO
-10.95%
$0.04
ABEV
+0.22%
$2.21
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
PLTR
+4.04%
$197.26
QS
+2.50%
$15.98
TSLA
+0.18%
$461.40
BBD
+4.13%
$3.53
DVLT
-13.05%
$2.80
CAN
-3.55%
$1.39
SRM
+53.27%
$10.30
RGTI
+6.19%
$39.36
BITF
+1.86%
$4.38
VZ
+2.17%
$40.17
CJET
-40.67%
$0.05
LUMN
+9.43%
$10.99
RIG
+2.26%
$3.83
NIO
+0.71%
$7.09
TLRY
+1.02%
$1.39
WULF
-3.85%
$15.32
JAMF
+15.15%
$12.84
PFE
+0.07%
$24.51
NAKA
+6.74%
$0.98
WLGS
-5.57%
$0.04
ACHR
+1.49%
$11.30
AMZN
+0.73%
$230.93
AMD
+0.80%
$260.08
JOBY
+8.58%
$16.95
ETWO
0.00%
$3.30
ETHD
+3.64%
$3.70
GRAB
+1.68%
$6.04
VALE
+2.46%
$11.90
CLSK
-5.19%
$19.14
QBTS
+5.76%
$33.84
IONZ
-13.01%
$3.61
AFMD
-34.94%
$0.18
PYPL
-2.30%
$71.34
AAPL
+0.10%
$269.27
AAL
+1.61%
$12.91
RXRX
+2.27%
$6.04
RR
-4.27%
$5.03
BAER
+0.88%
$1.71
AMCR
-3.53%
$8.05
OPI
-16.97%
$0.20
BTBT
+1.86%
$3.83
ONDS
+0.81%
$6.84
NXE
+12.00%
$9.52
KLG
-9.05%
$13.35
KHC
-4.80%
$24.29
ADTX
-18.33%
$0.10
AMC
-1.10%
$2.69
BE
+22.40%
$138.66
ERIC
+3.73%
$10.12
GRYP
-10.38%
$1.38
VRNS
-44.66%
$34.85
AVTR
-18.10%
$12.35
PCG
-1.88%
$16.12
MODV
-25.22%
$0.43
PLTD
-3.87%
$6.19
BTG
-1.12%
$4.84
QUBT
+3.78%
$15.47
CIFR
-0.07%
$19.94
AUR
-2.98%
$5.04
APLD
+0.69%
$34.57
WBD
+1.37%
$21.27
NGD
+0.15%
$6.33
RIVN
+2.25%
$13.80
HBAN
-0.87%
$15.40
SNAP
+1.93%
$7.89
NVTS
+5.66%
$13.55
XHLD
-14.11%
$0.36
AKBA
-26.07%
$2.28
LAES
+0.78%
$6.42
MARA
+0.39%
$18.95
PPBT
+57.04%
$0.91
CMBM
+259.22%
$2.22
GPUS
-24.33%
$0.41
NVDA
+3.31%
$207.70
ERNA
+54.53%
$1.93
SOFI
+5.53%
$31.66
BYND
-5.56%
$1.86
PFSA
+5.44%
$0.30
VHAI
-25.00%
$0.00
NOK
-5.27%
$7.36
MSAI
+28.82%
$1.09
ASST
-9.72%
$1.30
YDKG
-6.65%
$0.05
PLUG
+3.93%
$2.89
KDLY
-8.99%
$0.91
FI
-40.78%
$74.71
F
+1.22%
$13.29
AXDX
-61.36%
$0.03
BURU
-6.02%
$0.35
DNN
+3.90%
$3.19
VSEE
+12.26%
$1.19
INTC
+0.20%
$41.61
FUBO
+3.98%
$3.78
T
-2.15%
$25.14
YYGH
+13.41%
$0.33
ADAP
-15.14%
$0.05
WTO
-10.95%
$0.04
ABEV
+0.22%
$2.21
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
PLTR
+4.04%
$197.26
QS
+2.50%
$15.98
TSLA
+0.18%
$461.40
BBD
+4.13%
$3.53
DVLT
-13.05%
$2.80
CAN
-3.55%
$1.39
SRM
+53.27%
$10.30
RGTI
+6.19%
$39.36
BITF
+1.86%
$4.38
VZ
+2.17%
$40.17
CJET
-40.67%
$0.05
LUMN
+9.43%
$10.99
RIG
+2.26%
$3.83
NIO
+0.71%
$7.09
TLRY
+1.02%
$1.39
WULF
-3.85%
$15.32
JAMF
+15.15%
$12.84
PFE
+0.07%
$24.51
NAKA
+6.74%
$0.98
WLGS
-5.57%
$0.04
ACHR
+1.49%
$11.30
AMZN
+0.73%
$230.93
AMD
+0.80%
$260.08
JOBY
+8.58%
$16.95
ETWO
0.00%
$3.30
ETHD
+3.64%
$3.70
GRAB
+1.68%
$6.04
VALE
+2.46%
$11.90
CLSK
-5.19%
$19.14
QBTS
+5.76%
$33.84
IONZ
-13.01%
$3.61
AFMD
-34.94%
$0.18
PYPL
-2.30%
$71.34
AAPL
+0.10%
$269.27
AAL
+1.61%
$12.91
RXRX
+2.27%
$6.04
RR
-4.27%
$5.03
BAER
+0.88%
$1.71
AMCR
-3.53%
$8.05
OPI
-16.97%
$0.20
BTBT
+1.86%
$3.83
ONDS
+0.81%
$6.84
NXE
+12.00%
$9.52
KLG
-9.05%
$13.35
KHC
-4.80%
$24.29
ADTX
-18.33%
$0.10
AMC
-1.10%
$2.69
BE
+22.40%
$138.66
ERIC
+3.73%
$10.12
GRYP
-10.38%
$1.38
VRNS
-44.66%
$34.85
AVTR
-18.10%
$12.35
PCG
-1.88%
$16.12
MODV
-25.22%
$0.43
PLTD
-3.87%
$6.19
BTG
-1.12%
$4.84
QUBT
+3.78%
$15.47
CIFR
-0.07%
$19.94
AUR
-2.98%
$5.04
APLD
+0.69%
$34.57
WBD
+1.37%
$21.27
NGD
+0.15%
$6.33
RIVN
+2.25%
$13.80
HBAN
-0.87%
$15.40
SNAP
+1.93%
$7.89
NVTS
+5.66%
$13.55
XHLD
-14.11%
$0.36
AKBA
-26.07%
$2.28
LAES
+0.78%
$6.42
MARA
+0.39%
$18.95
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.